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Background: Low body mass index (BMI) individuals starting antiretroviral therapy (ART) for HIV infection in
sub-Saharan Africa have high rates of death and loss to follow-up in the first 6 months of treatment. Nutritional
supplementation may improve health outcomes in this population, but the anticipated benefit of any intervention
should be commensurate with the cost given resource limitations and the need to expand access to ART in the
region.
Methods: We used Markov models incorporating historical data and program-wide estimates of treatment costs
and health benefits from the Zambian national ART program to estimate the improvements in 6-month survival
and program retention among malnourished adults necessary for a combined nutrition support and ART treatment
program to maintain cost-effectiveness parity with ART treatment alone. Patients were stratified according to World
Health Organization criteria for severe (BMI <16.0 kg/m2), moderate (16.00-16.99 kg/m2), and mild (17.00-18.49 kg/m2)
malnutrition categories.
Results: 19,247 patients contributed data between May 2004 and October 2010. Quarterly survival and retention were
lowest in the BMI <16.0 kg/m2 category compared to higher BMI levels, and there was less variation in both measures
across BMI strata after 180 days. ART treatment was estimated to cost $556 per year and averted 7.3 disability-adjusted
life years. To maintain cost-effectiveness parity with ART alone, a supplement needed to cost $10.99 per quarter and
confer a 20% reduction in both 6-month mortality and loss to follow-up among BMI <16.0 kg/m2 patients. Among BMI
17.00-18.49 kg/m2 patients, supplement costs accompanying a 20% reduction in mortality and loss to follow-up could
not exceed $5.18 per quarter. In sensitivity analyses, the maximum permitted supplement cost increased if the ART
program cost rose, and fell if patients classified as lost to follow-up at 6 months subsequently returned to care.
Conclusions: Low BMI adults starting ART in sub-Saharan Africa are at high risk of early mortality and loss to follow-up.
The expense of providing nutrition supplementation would require only modest improvements in survival and program
retention to be cost-effective for the most severely malnourished individuals starting ART, but interventions are unlikely
to be cost-effective among those in higher BMI strata.
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The rapid expansion of access to combination antiretro-
viral therapy (ART) for the treatment of HIV infection in
sub-Saharan Africa over the past decade has occurred
against a backdrop of persistent poverty, underdevelop-
ment, and widespread food insecurity [1,2]. Inadequate
protein and energy intake accelerates HIV-associated
weight loss and immunosuppression, and a low body mass
index (BMI; <18.5 kg/m2) at treatment initiation is associ-
ated with 2 to 6 fold increased mortality within 90 days
compared to higher BMI in several analyses from the re-
gion [3-6]. In an analysis from Zambia, 20% of persons
with a pre-treatment BMI <16 kg/m2, indicative of severe
malnutrition by World Health Organization (WHO) cri-
teria, were deceased after 6 months of ART and an add-
itional 18% were lost to follow-up [7]. While the etiology
of these early deaths is poorly understood, weight gain in
the immediate post-ART period is a predictor of long-
term survival in low BMI adults, suggesting that interven-
tions to promote nutritional rehabilitation on ART may
impact long-term outcomes [7-9].
The few published trials of macronutrient supplemen-
tation (i.e., products containing protein, carbohydrate
or fat sources rather than vitamins or minerals alone)
found heterogeneous effects on early ART adherence,
client retention, and health outcomes [10-15]. However,
the provision of supplementation at a program level will
require additional expenditures and resource allocation
at a time when many countries are still expanding to
meet the need for ART services. In lieu of a large pro-
spective trial, cost-effectiveness modeling provides a
framework to assess the opportunity costs and potential
benefits of a range of prevention, treatment and care op-
tions, and can be used to estimate the feasibility of intro-
ducing a new intervention using available data. In this
analysis, we use cost estimates from a recent analysis of
45 ART clinics in Zambia, in combination with health
outcomes data on over 19,000 patients, to model the
minimum improvements in survival and program reten-
tion necessary for a hypothetical combined nutrition
support and ART treatment program to maintain cost-
effectiveness parity with ART treatment alone [16].
Methods
The setting for this analysis was the Zambian national
program for HIV care and treatment, implemented in
April 2004 [3,17]. We constructed competing Markov
models to assess the circumstances under which the cost
per disability adjusted life year (DALY) averted resulting
from the addition of a nutrition supplement for 6 months
as an adjunct to ART treatment would be equally or more
cost-effective than standard treatment with ART. We se-
lected a 6 month intervention based on epidemiologic
studies from Zambia and other countries in sub-SaharanAfrica demonstrating that mortality rates are markedly
higher among low-BMI adults in the first 6 months of
ART treatment, and then normalize compared to higher
BMI groups after this period [4,7,8].
Our primary estimates of ART program costs and
health outcomes are drawn from a program-wide cost-
effectiveness analysis of HIV treatment and care in
Zambia, which tabulated costs at 45 public and private-
sector health centers from April 2004 through July 2008,
and reported facility-level unit costs as the full incremental
cost of providing ART divided by the number of person-
years on treatment [16]. We used this analysis as our base
estimate for two major reasons; first, many of the clinical
sites surveyed served the same patients comprising the
historical cohort used to derive our mortality and reten-
tion data. Second, the HIV epidemic in Zambia was char-
acterized by a high prevalence of advanced disease (i.e.,
AIDS) and an under-developed health system in the early
stages of the rapid scale-up of ART services beginning in
2004, which may have had unique effects on both program
costs and health effects. However, we also performed a
sensitivity analysis around the base ART cost estimate
using recent systematic reviews from the region [18-21].
Our data on mortality and loss to follow-up over the first
6 months of ART among malnourished adults starting
ART in Zambia are derived from a historical cohort of
58,380 adults (19,247 with BMI <18.5 kg/m2) receiving
ART in Zambia from May 2004 through October 2010.
These data were generated by the custodian of the national
ART program database for the purpose of this analysis and
stratified by WHO criteria: BMI <16.0 kg/m2 (severe mal-
nutrition), 16.00-16.99 kg/m2 (moderate malnutrition),
and 17.00-18.49 kg/m2 (mild malnutrition) [22].
We used Markov models to portray disease progression
through a series of distinct states; in our model, individ-
uals were (1) alive and active in care, (2) deceased, or (3)
lost to follow-up from the treatment program. Transition
state probabilities were drawn from the historical cohort
data and were unidirectional; patients in the deceased and
lost to follow-up terminal states could not transition back
to the alive and active in care state (a separate sensitivity
analysis modeled patients classified as lost at 6 months
who subsequently returned to the program). Each model
cycle represented a 90 day period, and patients remaining
alive and active in care at the completion of 2 model cycles
(approximately 6 months) were assigned a fixed lifetime
program cost and health outcome. We modeled the po-
tential effect of nutrition supplementation on the rate of
transition to the deceased or lost to follow-up states using
survival and retention probabilities, which represent
projected proportional reductions in historical mortality
and loss to follow-up rates as a result of implementing a
supplementation program. Figure 1 describes the model
design.
Competing Markov models
(stratified by pre-treatment BMI)
Standard treatment versus food 
supplementation at ART initiation
1 cycle = one quarter (90 days)
Standard treatment strategy:
Cycle-specific inputs:
Patients on ART at start of quarter
Historical survival and retention data
Non-cycle specific input:
ART cost per quarter ($139)*
Food supplementation strategy:
Cycle-specific inputs:
Patients on ART at start of quarter
Historical survival and retention data
Non-cycle specific inputs:
ART cost per quarter ($139)
Supplement cost per quarter (2 cycles)
Supplement survival probability (<1.0)
Supplement retention probability (<1.0)
Patients 
deceased 





at end of 
quarter Additional costs and benefits 
for patients remaining alive and 
in treatment at the completion 
of 2 cycles:




7.3 DALYs averted†Patients 
deceased 






at end of 
quarter
(modified)
2 cycles (180 days)
2 cycles (180 days)
Figure 1 Design of the cost-effectiveness model. *ART cost per quarter calculated as the average cost per ART year ($556) divided by four.
This figure represents year one costs and is not subject to discounting. **Added lifetime cost per active ART patient is calculated by subtracting
cumulative ART cost accrued during 2 model cycles from an overall cost of $6,118 per death averted, or the lifetime expenditure per patient
(discounted at a rate of 3% and accounting for historical rates of second-line ART use). Cost estimates for ART and the switch rate from first to
second-line treatment are from a PEPFAR-supported, program-wide cost-effectiveness analysis of 45 public and private-sector centers providing
HIV treatment in Zambia between 2004 and 2008.
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treatment in each BMI stratum was calculated using the
historical survival and retention rates, which provided the
willingness to pay (WTP) value. The WTP value repre-
sents the benchmark cost-effectiveness for assessing com-
binations of supplement costs and relative reductions in
survival and/or loss to follow-up. If the program cost per
DALY averted for a given combination of supplement cost
and survival/retention improvement exceeds the WTP
value of ART alone, the combination is considered less
cost effective than standard ART provision.
Using the WTP values for each BMI stratum as a
threshold, we calculated the maximum quarterly supple-
ment costs permitted to maintain parity with ART treat-
ment alone for four hypothetical scenarios: first, if the
added costs of supplement conferred only a 20% reduction
in mortality; second, only a 20% reduction in loss to
follow-up; third, a 20% reduction in both endpoints; or
fourth, a 50% reduction in both endpoints. We then com-
pared the maximum permitted quarterly supplement costs
for each of these four scenarios against the cost of provid-
ing half of an HIV patient’s recommended daily caloric in-
take for 90 days using several supplements common to
the region.
Lastly, to demonstrate the effects of selecting a more
expensive supplement product over a less expensive
product, we graphed the effects of interval increases in
quarterly supplement costs against the necessary change
in proportional reduction in mortality and/or loss to
follow-up required to maintain parity with ART treat-
ment alone in each low BMI stratum.Clinical estimates
Survival
Baseline quarterly estimates of survival on ART were
drawn from a historical cohort of 58,380 adults (19,247
with BMI <18.5 kg/m2) initiating treatment at Lusaka
district health clinics between May 1, 2004 and October
1, 2009, with clinical follow-up through October 1, 2010
(Table 1). BMI-stratified hazard ratios for death were
calculated at 90 day intervals from ART initiation to 360
days.
Retention
Baseline quarterly estimates of program retention were
calculated using the same historical cohort. Loss to
follow-up was defined according to the internal pro-
grammatic definition of no return to clinic within 37
days after a scheduled pharmacy visit or within 60 days
of the last clinical visit if no pharmacy visit was sched-
uled. A sensitivity analysis assessed the effect of varying
proportions of patients classified as lost to follow-up
subsequently returning to the ART program.
Health outcomes
Cost-effectiveness was portrayed as the program cost per
DALY averted, an indicator of the time lived with a disabil-
ity and the time lost due to premature mortality [23].
Treatment with ART was estimated to avert 7.3 dis-
counted DALYs among HIV-infected individuals who sur-
vived >16 weeks. This value was drawn from the same
Zambian analysis used to estimate treatment costs, and
it was obtained by comparing deaths in the Zambian
Table 1 Clinical and cost estimates in the cost-effectiveness model
Historical quarterly survival and loss to follow-up in the Zambian national ART program from May 2004 through October 2010 stratified
by BMI*
BMI (kg/m2) Quarter Patients alive/active at start of quarter Disposition at end of quarter (%/cumulative %)
Alive/active Dead Loss to follow-up
<16.0 Q1; 0-90 days 5096 3649 (71.6 / na) 881 (17.3 / na) 566 (11.1 / na)
Q2; 91-180 days 3649 3131 (85.8 / 61.4) 181 (5.0 / 20.8) 337 (9.2 / 17.7)
Q3; 181-270 days 3131 2875 (91.8 / 56.4) 73 (2.3 / 22.3) 183 (5.8 / 21.3)
Q4; 271-360 days 2875 2689 (93.5 / 52.8) 40 (1.4 / 23.1) 146 (5.1 / 24.2)
16.00 - 16.99 Q1 4439 3608 (81.3 / na) 468 (10.5 / na) 363 (8.2 / na)
Q2 3608 3222 (89.3 / 72.6) 124 (3.4 / 13.3) 262 (7.3 / 14.1)
Q3 3222 2995 (93.0 / 67.5) 45 (1.4 / 14.4) 182 (5.7 / 18.2)
Q4 2995 2813 (93.9 / 63.4) 34 (1.1 / 15.1) 148 (4.9 / 21.5)
17.00 - 18.49 Q1 9712 8421 (86.7 / na) 631 (6.5 / na) 660 (6.8 / na)
Q2 8421 7630 (90.6 / 78.6) 228 (2.7 / 8.8) 563 (6.7 / 12.6)
Q3 7630 7177 (94.1 / 73.9) 103 (1.4 / 9.9) 350 (4.6 / 16.2)
Q4 7177 6849 (95.4 / 70.5) 58 (0.8 / 10.5) 270 (3.8 / 19.0)
>18.5 Q1 39133 35716 (91.3 / na) 1229 (3.1 / na) 2188 (5.6 / na)
Q2 35716 33417 (93.6 / 85.4) 460 (1.3 / 4.3) 1839 (5.1 / 10.3)
Q3 33417 31850 (95.3 / 81.4) 251 (0.8 / 5.0) 1316 (3.9 / 13.7)
Q4 31850 30432 (95.5 / 77.8) 200 (0.6 / 5.5) 1218 (3.8 / 16.8)
Cost estimates (all BMI strata)
ART treatment $556 per year ($139 per quarter)
Health outcomes estimate (all BMI strata)
Health benefits per AIDS death averted 7.3 Disability-adjusted life years
*Derived from a historical cohort of 58,380 patients initiating ART in Lusaka district health clinics between May 1, 2004 and October 1, 2009; 19,247 (33%) had a
baseline BMI <18.5 kg/m2.
Abbreviations: ART antiretroviral therapy, BMI body mass index.
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characterized home-based AIDS care (HBAC) cohort of
466 HIV-infected patients not receiving ART in Tororo
District, Uganda, adjusted for differences in CD4+ T-cell
counts and sex distribution between groups [16,19,24,25].
Cost estimates
First-line ART
The unit cost estimate for antiretroviral agents and
ART-related health care per person-year (i.e., an ART-
year) was drawn from the cost-effectiveness analysis of
45 treatments sites across Zambia [16]. The sites were
predominantly publically-funded (87%), urban (84%),
and located in clinics (64%) as opposed to hospitals. The
overall program cost was estimated to be $69.7 million
for 125,436 person-years of ART delivered between
April 26, 2004 and July 1, 2008, or a pooled average of
$556 per ART-year (adjusted to 2010 US dollars accord-
ing to the consumer price index).The cost per death
averted, or the lifetime program cost per patient was
$6,118 (discounted at a rate of 3% and accounting for
historical rates of second-line ART use).While our primary cost estimate is similar to another
recently published analysis from Zambia which found a
cost of $518 to $523 per year for the use of efavirenz
and non-generic tenofovir and emtricitabine (the recom-
mended first-line NRTI combination in Zambia since
2007), there was also a high degree of heterogeneity in
the average total (i.e., on site and off site) cost at the 45
sites used to derive our estimates, which explained 78%
and 66% of the variation of average total and on-site
costs respectively [16,18]. For this reason, we also con-
ducted a sensitivity analysis incorporating cost estimates
from recent systematic reviews of similar low income
countries [20,21].
Our analysis did not consider direct non-health care
costs and hospitalization costs, which are an important
and often expensive component of overall health care
expenditures. First, while we have rigorously collected
data on ART costs and survival/retention from the
Zambia ART program, we do not have similarly rigorous
data on per-patient health care costs for end-stage AIDS,
hospice costs, and other end-of-life costs in Zambia.
Given the multitude of non-governmental organizations
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Zambia during the study period, it would be difficult to
estimate the proportion of costs that were actually borne
by the public sector. Second, we are primarily concerned
with the implementation of a nutrition supplementation
program within the funding framework of a dedicated
ART treatment program. Such programs, often supported
heavily by international donors such as the Presidents
Emergency Plan for AIDS Relief (PEPFAR), are primarily
designed for the delivery of ART services and may not
support other health infrastructure including general facil-
ities and hospice care.
Nutrition supplements
The range of nutrition supplement costs included in our
analysis was informed by contemporary prices for staple
commodities consumed in the region [26] and common
macronutrient supplements utilized by the World Food
Program (WFP) such as corn-soya blend flour (CSB)
[26] and Ready-to-Use Therapeutic Food (RUTF) [27,28]
(Table 2). Cost estimates were drawn from the literature
and United Nations Food and Agricultural Organization
historical global food prices [12,29]. The quarterly cost
of each supplement was based on the quantity necessary
to supply a daily target of 1,360 kcal, which representsTable 2 Comparison of nutritional content and estimated cos
Ready-to-use therapeutic food [27,28
Grams: 100
Calories: 557
Protein grams (% kcal): 14 (10%)
Fat grams (% kcal): 35 (59%)
Carbohydrate % kcal: 31%
Indication: Moderate to severe malnutrition
Ingredients: Plumpy’Nut: vegetable fat, peanut paste
skimmed milk powder, whey powder,
malto-dextrin, sugar, mineral and vitami
complex.
Kilograms needed to supply
1,360 kcal/day for 3 months*
21.97
Estimated cost per kilogram (USD) $2.18†
Estimated cost to provide
1,360 kcal/day for 3 months (USD)Ω
$47.89
Note: cost-effectiveness models provide a threshold value for supplement costs, ho
local cost of delivering the supplement to patients.
*The figure of 1,360 kcal/day represents 50% of the WFP recommended minimum d
limit of the estimated increase in resting metabolic rate in advanced HIV infection).
†Reported costs per kilogram for locally produced, peanut-based ready-to-use sprea
by Ndekha et al. [12].
‡Annual average price in 2012 for US #2 yellow maize and white broken rice (Thai
(http://www.fao.org/es/esc/prices). Current prices may be higher.
ΩExcludes all external costs (transport, storage, etc.).50% of the WFP recommended minimum daily intake of
2100 kcal for adults, increased by an additional 30% (the
upper limit of the estimated increase in resting meta-
bolic rate in advanced HIV infection) [30,31]. Because
nutrition supplementation is only modeled for the first 6
months of ART, costs were not discounted.
Sensitivity analyses
We performed sensitivity analyses around ART program
costs and the effect of patients classified as lost to
follow-up subsequently returning to care. Both sensitiv-
ity models assume a 20% mortality and 20% loss to
follow-up reduction from the supplement to calculate
the maximum supplement costs which would be cost-
effective compared to standard treatment across a range
of input values. To assess the effect of ART program
costs, we utilized estimates from a recent systematic re-
view of six studies in four low income countries that
found a median cost per ART patient-year of $792 and a
range of $682 to $1,089, which was similar to other sys-
tematic reviews from the region [20,21,32]. The upper
bound of this range is approximately 196% of our esti-
mate of $556 per year, and the sensitivity analysis con-
siders ART costs ranging from $500 to $1200 per
patient-year ($125 to $300 per quarter).ts of potential supplements
] Corn-soya blend flour [26] Common sub-Saharan







17 (18%) 8.5 (9%) 7.1 (8%)
7.0 (17%) 1.7 (4%) 0.7 (2%)
65% 87% 90%
Mild to moderate malnutrition Staple food Staple food
,
n
Corn and soy blend flour, soybean oil,




wever the selection of a specific product would be highly dependent on the
aily intake of 2100 kcal for adults, increased by an additional 30% (the upper
d and corn-soya blend flour from a nutrition supplementation trial in Malawi
A1 Super). Source: Food and Agriculture Organisation of the United Nations
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in the first 6 months of treatment as permanent exits
from the HIV program, and while a large systemic re-
view found approximately 40% of African ART patients
lost to follow-up early in treatment represent unre-
corded deaths, a proportion of the lost patients will
eventually return to care [33]. For this reason, we mod-
eled the effect of 20% to 80% of patients classified as lost
subsequently returning to care and contributing to life-
time ART costs and DALYs averted (we assumed they
would not receive a second course of supplementation).
Analysis software
Survival and retention estimates were calculated from
the historical cohort data using SAS version 9.1 (SAS
Institute, Cary, North Carolina). Markov modeling and
cost-effectiveness analyses were performed using Tree-
Age Pro Healthcare module (Version 2014, TreeAge
Software, Inc. Massachusetts, USA).
Results
Survival and retention in the historical cohort
Among 58,380 patients starting ART in Lusaka district
health clinics between May 1, 2004 and October 1, 2009,
19,247 (33%) had a BMI <18.5 kg/m2 at treatment initi-
ation. Among those with BMI <16.0 kg/m2, 17.3% were
deceased before 90 days and 20.8% by 180 days, while
11.1% and 17.7% were classified as lost to follow-up at
the same time points (Table 1). In contrast, 3.1% of pa-
tients with a BMI >18.5 kg/m2 were deceased at 90 days,
and 5.6% were lost to follow-up. Quarterly survival and
retention generally improved as BMI increased, and
there was minimal variation in rates between BMI cat-
egories after 180 days of treatment. Within the malnour-
ished BMI strata, the BMI <16.0 kg/m2 group had a
slightly higher proportion of women compared to the
BMI 17.00-18.49 kg/m2 group (59% versus 53%), lower
median age (33 versus 35 years), and a lower median
CD4+ T-cell count (92 versus 127 cells/μl).
Effect of changes in survival and retention probability on
cohort health outcomes
The anticipated effect on overall 6 month treatment out-
comes resulting from a proportional reduction in the
historical quarterly mortality and loss to follow-up rates
(modeled as zero to 50%) varied across the BMI strata
(Figure 2). The projected improvements in the number
of patients alive and active in care was most pronounced
in the BMI <16.0 kg/m2 category; for every 100 patients
initiating ART, approximately 18 additional individuals
were estimated to remain alive and active in care at 6
months when both the historical mortality and loss to
follow-up rates were reduced by 50%. In the BMI 17.00-
18.49 kg/m2 category, similar reductions resulted inapproximately 10 more patients alive and in care at 6
months.
Cost-effectiveness requirements for nutritional
supplement intervention
The WTP values, or the benchmark cost-effectiveness of
standard ART treatment against which alternate inter-
ventions can be compared, were $853.31, $847.53, and
$845.87 per DALY averted in the BMI <16.0, 16.00-
16.99, and 17.00-18.49 kg/m2 categories, respectively.
The WTP values varied across the BMI categories as a
function of the historical mortality and loss to follow-up
rates in each category; because a greater proportion of
BMI <16.0 kg/m2 persons accrued early ART costs but
ultimately failed to survive, the cost per DALY averted is
higher in this group.
Using the WTP values for each BMI stratum, we mod-
eled four hypothetical scenarios: first, if the added costs of
supplement conferred only a 20% reduction in mortality;
second, if the supplement conferred only a 20% reduction
in loss to follow-up; third if the supplement conferred a
20% reduction in both endpoints; or fourth, if the sup-
plement conferred a 50% reduction in both endpoints
(Table 3). Based on published costs in the literature and
United Nations Food and Agricultural Organization his-
torical global food prices, the provision of 1360 kcal/day
for 3 months was estimated to cost $9.90 using maize
flour, $15.66 for CSB, and $47.89 for RUTF in 2012
(Table 2) [12,29]. Therefore, the provision of maize sup-
plement to individuals with a BMI <16.0 kg/m2 would be
cost-effective if accompanied by a combined 20% reduc-
tion in mortality and 20% reduction in loss to follow-up,
while the provision of CSB would be cost-effective if ac-
companied by a 50% combined reduction. In the BMI
16.00-16.99 kg/m2 category, supplementation with CSB
was cost-effective if accompanied by a combined 50% re-
duction in mortality and loss to follow-up, while in the
17.00-18.49 kg/m2 category only maize would be cost-
effective if the same endpoint was achieved. While our
models provide a threshold cost-effectiveness value for the
intervention, the selection of a specific product would be
highly dependent on the local cost of delivering the sup-
plement to patients. In particular, local mass production
of RUTF might be considerably less expensive compared
to costs reported in clinical studies [12].
Lastly, we plotted interval increases in quarterly sup-
plement costs against the proportional reduction in mor-
tality and/or loss to follow-up necessary to maintain
parity with ART treatment alone in each low BMI
stratum (Figure 3). For each quarterly supplement cost
value, the accompanying reduction in mortality and loss
to follow-up would need to fall below the diagonal line
to be more cost-effective than standard treatment. The
range of quarterly supplement prices that would be
Figure 2 Estimated percentage of patients remaining alive and on antiretroviral therapy at 6-months as a result of proportional
reductions in the historical quarterly death and loss to follow-up rates, stratified by BMI. The effect of a proportional reduction in
quarterly loss to follow-up rates is represented by the diagonal lines, and the effect of a reduction in quarterly mortality rates is shown on the
x-axis. Locate a mortality reduction value (0 to 50%) on the given loss to follow-up reduction line, and the percentage of patients estimated to
remain alive and on ART at 6 months as a result of the assumed changes is shown on the y-axis. The historical program retention rate
corresponds to the y-intercept of the lowest diagonal line (i.e., no assumed reduction in loss to follow-up). Abbreviations: ART, antiretroviral
therapy; BMI, body mass index.
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creased. Interventions resulting in a 20% reduction in
both mortality and loss to follow-up were cost-effective
in the BMI <16.0 kg/m2 stratum if less than approxi-
mately $10 per quarter or less than $5 per quarter in the
BMI 17.00-18.45 kg/m2 stratum, while the maximum
permitted intervention costs in the model, correspond-
ing to a combined 50% survival and retention improve-




We modeled the effects of ART program patient-year
costs ranging from $500 to $1200 (90% to 216% of our
base estimate) on the cost-effectiveness of a supplement
conferring a 20% reduction in both survival and retention
(Additional file 1: Table S1 and Additional file 2: Figure
S1). In the BMI <16 kg/m2 stratum, the maximum permit-
ted quarterly supplement cost rose from $10.99 to $23.83
if the cost per patient-year of ART was increased from our
base estimate of $556/year to $1200/year. A similar effect
was observed in the higher BMI strata, but the magnitudeTable 3 Maximum allowable quarterly supplement costs to m
BMI category
Change in overall survival and retention at 6 months of ART with supp
20% mortality benefit, no retention benefit
No mortality benefit, 20% retention benefit
20% mortality and 20% retention benefit
50% mortality and 50% retention benefit
*scenarios in which maize flour supplementation would be cost-effective.
†scenarios in which maize flour or corn-soya blend flour supplementation would beof the increase in permitted supplement costs was not as
pronounced as ART program costs increased.Return to care of patients classified as lost to follow-up
We modeled the effect of 20% to 80% of patients classified
as lost to follow-up at 6 months subsequently returning to
the ART program and resuming care (Additional file 3:
Table S2 and Additional file 4: Figure S2). We utilized our
base ART cost ($139/quarter) and assumed returned pa-
tients would generate the same lifetime ART costs and
DALYs averted as patients remaining in care at 6 months
from initial ART start (returned patients would not receive
a second course of supplementation). The model assumes
a 20% reduction in both survival and retention from the
intervention. As expected, the maximum permitted sup-
plement cost decreased as more patients returned to care,
with the greatest decline in the BMI <16 kg/m2 stratum
(the group with the highest loss to follow-up rate).Discussion
Our analysis of the effects of a nutrition supplementation
program for HIV-infected, low BMI adults starting ARTaintain parity with ART alone






Figure 3 Proportional reductions in mortality and loss to follow-up necessary to maintain parity with antiretroviral therapy alone for
different quarterly supplement costs, stratified by BMI. Quarterly supplement costs are represented by diagonal lines. Projected reductions in
the historical quarterly mortality and loss to follow-up rates are plotted on the x-axis and y-axis, respectively. For a given quarterly supplement
cost, the combination of the proportional reduction in mortality and loss to follow-up would need to fall below the diagonal line to be more
cost-effective than ART treatment alone. Abbreviations: ART, antiretroviral therapy; BMI, body mass index.
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health outcomes data with program-wide cost data to de-
fine minimum improvements in survival and program
retention necessary to maintain cost-effectiveness parity
with ART treatment alone. A 6-month supplementation
program was potentially cost effective in comparison to
standard treatment in all categories of clinical malnutri-
tion, but the permitted supplement costs were markedly
lower for patients with higher pre-treatment BMI. Our re-
sults can be used to set retention and survival targets, and
an acceptable supplement cost range, for future prospect-
ive macronutrient intervention trials to reduce the start-
lingly high early mortality rate in this population.
In designing a trial of nutrition supplementation, costs
should be balanced against reasonable assumptions about
the anticipated effects. The incremental reduction in mor-
tality and/or loss to follow-up necessary to justify an inter-
val rise in quarterly supplement costs was smallest in the
BMI <16.0 kg/m2 category, suggesting that more severely
malnourished individuals may be a preferred population
for future trials if cost-effectiveness is a concern. However,
while cost is an important input variable, the effectiveness
of a supplement for achieving the desired endpoint is
equally important. Additional studies to characterize the
nutritional deficits present in HIV-infected adults with
low BMI are needed to determine the optimal supplement
composition. For example, the provision of carbohydrate-
rich, low-cost local staple foods, such as cornmeal, rice, or
green banana, may appear to be the preferred intervention
to reduce the supplement cost and maximize cost-
effectiveness. However, a predisposition to protein catabol-
ism (especially skeletal muscle) over adipose tissue in HIV
infection [34], and an elevated rate of protein turnover
[35,36], suggest that low-protein foods may performpoorly for nutritional rehabilitation of severely wasted pa-
tients with significant muscle mass reduction [37]. While
RUTF is considerably more expensive than maize, RUTF
contains far higher fat and protein, which may be of bene-
fit to persons with advanced muscle wasting. Similarly,
CSB provides a higher percentage of calories from protein
and fat compared to local staple foods at a much lower
cost than RUTF, and may represent a cost-effective option
for patients in the BMI <16.0 kg/m2 stratum if the survival
and retention benefits are in the 10-15% range.
A potential limitation of our analysis was the reliance
on a single DALY estimate drawn from prior studies of
ART cost-effectiveness in Zambia and Uganda, which
utilized disability weights from the 2002 Global Burden
of Disease (GBD) study [38]. The more recent disability
weights from the 2010 GBD study approximate the
values used to derive our estimate of 7.3 DALYs averted
by ART treatment. We used a disability weight of 0.06
for calculating the benefits of ART versus 0.053 in the
2010 GBD report, an estimate of 0.505 for AIDS not re-
ceiving ART versus 0.547, and an estimate of 0.221 for
untreated HIV prior to the development of AIDS versus
0.135 [39]. The major difference between the 2002
GBD disability weights used in our analysis and the
2010 update relate to untreated HIV prior to the devel-
opment of AIDS. However, in the cohort used to derive
our estimates, which was typical of many sub-Saharan
African countries at the time, advanced HIV disease
(i.e. AIDS) was far more common among those pre-
senting for treatment than early-stage HIV. In a sensi-
tivity analysis applying the 2010 GBD disability weights
to the Zambian ART program analysis, we found the
estimated DALYs averted by ART treatment changed
by only 2.6% [16].
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could bias the results by either underestimating or over-
estimating the cost-effectiveness of nutrition supplemen-
tation. While we included the direct costs of HIV care
and ART medications at facilities supported by PEPFAR,
we did not consider the additional public-sector health
costs associated with patients lost to follow-up and ad-
mitted to a hospital with advanced disease. Additionally,
our approach may have underestimated the additional
costs incurred by low BMI patients who ultimately sur-
vive as a result of nutrition supplementation but require
costly additional monitoring or care in the early post-
ART period. Our model also did not address the effect
of nutrition supplementation on ART adherence, which
has been reported in prior studies and could lead to im-
proved maintenance of viral suppression and reduced
costs for expensive second-line agents [10,15].
Conclusions
In a population of HIV-infected malnourished adults in
Zambia, the minimum proportional reductions in morta-
lity and loss to follow-up necessary for a combined nutri-
tion support and ART treatment program to maintain
cost-effectiveness parity with ART alone appear to be rea-
sonable endpoints for prospective studies utilizing several
candidate supplements. Our analysis methodology can be
used to evaluate the cost-effectiveness of future trials of
macronutrient supplementation to reduce the high early
mortality rate among low BMI adults, utilizing contem-
porary commodity prices and historical health outcomes
specific to a given population. Malnourished adults repre-
sent a particularly vulnerable population in critical need of
innovative interventions to improve early ART outcomes,
and cost-effectiveness targets for clinical studies are a
means to ensure limited health resources can be used to
greatest benefit.
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